Andrology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 29, 2024
Abstract
Prostate
cancer
remains
a
lethal
disease
for
many
men.
Knowledge
of
genetic
contributions
to
this
condition
has
increasingly
been
used
in
its
management.
In
narrative
review,
we
summarize
various
alterations
and
syndromes
associated
with
prostate
cancer,
including
hereditary
breast
ovarian
syndrome,
Lynch
among
others.
Indications
germline
testing
are
reviewed,
as
well
incorporation
data
at
different
phases
management
such
screening
monitoring,
treatment
localized
metastatic
disease.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(16), P. 2777 - 2777
Published: Aug. 6, 2024
Castration-resistant
prostate
cancer
(CRPC)
remains
a
significant
therapeutic
challenge
due
to
its
resistance
standard
androgen
deprivation
therapy
(ADT).
The
emergence
of
receptor
splice
variant
7
(AR-V7)
has
been
implicated
in
CRPC
progression,
contributing
treatment
resistance.
Current
treatments,
including
first-generation
chemotherapy,
blockers,
radiation
therapy,
immune
and
PARP
inhibitors,
often
come
with
substantial
side
effects
limited
efficacy.
Natural
compounds,
particularly
those
derived
from
herbal
medicine,
have
garnered
increasing
interest
as
adjunctive
agents
against
CRPC.
This
review
explores
the
role
AR-V7
highlights
promising
benefits
natural
compounds
complementary
treatments
conventional
drugs
reducing
overcoming
We
delve
into
mechanisms
action
underlying
anti-CRPC
showcasing
their
potential
enhance
outcomes
while
mitigating
associated
therapies.
exploration
offers
avenues
for
developing
novel
strategies
that
reduce
adverse
These
provide
safer,
more
effective
approach
managing
CRPC,
representing
advancement
improving
patient
care.
Frontiers in Molecular Biosciences,
Journal Year:
2024,
Volume and Issue:
11
Published: Nov. 22, 2024
Proteolysis-targeting
chimeras
(PROTACs)
offer
a
groundbreaking
approach
to
selectively
degrade
disease-related
proteins
by
utilizing
the
ubiquitin-proteasome
system.
While
this
strategy
shows
great
potential
in
preclinical
and
clinical
settings,
off-tissue
effects
remain
major
challenge,
leading
toxicity
healthy
tissues.
This
review
explores
recent
advancements
aimed
at
improving
PROTAC
specificity,
including
tumor-specific
ligand-directed
PROTACs,
pro-PROTACs
activated
tumor
environments,
E3
ligase
overexpression
strategies.
Innovations
such
as
PEGylation
nanotechnology
also
play
role
optimizing
efficacy.
These
developments
hold
promise
for
safer,
more
effective
cancer
therapies,
though
challenges
translation.
Andrology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 29, 2024
Abstract
Prostate
cancer
remains
a
lethal
disease
for
many
men.
Knowledge
of
genetic
contributions
to
this
condition
has
increasingly
been
used
in
its
management.
In
narrative
review,
we
summarize
various
alterations
and
syndromes
associated
with
prostate
cancer,
including
hereditary
breast
ovarian
syndrome,
Lynch
among
others.
Indications
germline
testing
are
reviewed,
as
well
incorporation
data
at
different
phases
management
such
screening
monitoring,
treatment
localized
metastatic
disease.
